Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", ...

Medtronic PLC’s stock fell 7.3% as the worst performer in the S&P 500 on Tuesday after the medical-products company’s earnings fell slightly short of Wall Street’s revenue target despite a ...

Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U.S. President Donald Trump's tariff plans, a company ...

Medtronic's diversified product portfolio aimed at a wide range of chronic diseases spans therapeutic areas including cardiac, diabetes, chronic pain, as well as various products for acute care.

Kaplan, Robert S., Michael E. Porter, Thomas W. Feeley, and Alee Hernandez. "Medtronic: Navigating a Shifting Healthcare Landscape." Harvard Business School Case 718 ...